Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.43 |
| ▸ | PKM | P14618 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7223994 | 0.90 | POLB (0.36) | ALDH1A1PKMKMT2AMAPTLMNA | |
| SCHEMBL7228473 | 0.90 | MAPT (0.40) | ALDH1A1KMT2AMAPTLMNAMEN1 | |
| SCHEMBL7223364 | 0.88 | POLB (0.45) | ALDH1A1KMT2AMEN1POLBCYP3A4 | |
| SCHEMBL8958259 | 0.87 | RAB9A (0.34) | ALDH1A1PKMKMT2AMAPTLMNA | |
| SCHEMBL7230766 | 0.87 | POLB (0.42) | ALDH1A1KMT2AMAPTLMNAMEN1 | |
| SCHEMBL7229750 | 0.86 | PKM (0.62) | ALDH1A1PKMKMT2AMAPTLMNA | |
| SCHEMBL8957820 | 0.86 | THRA (0.38) | KMT2AMAPTLMNAMEN1SMN1; SMN2 | |
| SCHEMBL7225323 | 0.85 | HDAC3 (0.42) | ALDH1A1KMT2AMAPTLMNAMEN1 | |
| SCHEMBL8957970 | 0.85 | CA12 (0.41) | ALDH1A1GAA | |
| SCHEMBL8958011 | 0.85 | POLB (0.33) | ALDH1A1KMT2AMAPTLMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1112356-C | Nitromethylthiobenzene derivatives as inhibitors of aldose reductase | MERCK PATENT GMBH (DE) | 2003-06-25 | — | — | CN | claimed |
| EP-0408713-B1 | PHENYLSULPHONE DERIVATIVES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-05-19 | — | — | EP | claimed |
| EP-0408713-A1 | PHENYLSULPHONE DERIVATIVES. | ICI PLC (GB) | 1991-01-23 | — | — | EP | claimed |
| WO-1990008761-A1 | PHENYLSULPHONE DERIVATIVES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1990-08-09 | — | — | WO | claimed |
| US-20030203966-A1 | Nitromethylthiobenzene derivatives as aldose reductase inhihibitors | COLLONGES FRANCOIS (FR) | 2003-10-30 | — | — | US | disclosed |
| CN-1112356-C | Nitromethylthiobenzene derivatives as inhibitors of aldose reductase | MERCK PATENT GMBH (DE) | 2003-06-25 | — | — | CN | disclosed |
| US-6509499-B1 | Nervous system disorders, vision defects, diabetic retinopathy, neuropathic pain and kidney disorder treatment | MERCK PATENTGESELLSCHAFT MIT (DE) | 2003-01-21 | — | — | US | disclosed |
| EP-0946503-B1 | NITROMETHYLTHIOBENZENE DERIVATIVES AS INHIBITORS OF ALDOSE REDUCTASE | MERCK PATENT GMBH (DE) | 2002-03-27 | — | — | EP | disclosed |
| CN-1241997-A | Nitromethylthiobenzene derivatives as inhibitors of aldose reductase | MERCK PATENT GMBH (DE) | 2000-01-19 | — | — | CN | disclosed |
| EP-0946503-A1 | NITROMETHYLTHIOBENZENE DERIVATIVES AS INHIBITORS OF ALDOSE REDUCTASE | MERCK PATENT GmbH (DE) | 1999-10-06 | — | — | EP | disclosed |
| WO-1998028265-A1 | NITROMETHYLTHIOBENZENE DERIVATIVES AS INHIBITORS OF ALDOSE REDUCTASE | MERCK PATENT GMBH (DE) | 1998-07-02 | — | — | WO | disclosed |
| EP-0469889-B1 | (p-Carbonylaminophenyl)-sulphonyl-nitromethane derivatives | ZENECA LTD (GB) | 1996-01-17 | — | — | EP | disclosed |
| US-5189031-A | Inhibitor of enzyme aldose reductase, useful in the treatment of certain peripheral effects of diabetes and galactosemia | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-02-23 | — | — | US | disclosed |
| US-5153227-A | Treatment of diabetes and galactosemia complications | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1992-10-06 | — | — | US | disclosed |
| US-5110808-A | Aldose reductase inhibitors; peripheral effects of diabetes and galactosemia | IMPERIAL CHEMICAL INDUSTRIES, PLC (GB) | 1992-05-05 | — | — | US | disclosed |
| EP-0469887-A1 | Acetamide derivatives | ZENECA LIMITED (GB) | 1992-02-05 | — | — | EP | disclosed |
| EP-0469888-A1 | Amidobenzenes | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1992-02-05 | — | — | EP | disclosed |
| EP-0469889-A1 | (p-Carbonylaminophenyl)-sulphonyl-nitromethane derivatives | ZENECA LIMITED (GB) | 1992-02-05 | — | — | EP | disclosed |
| EP-0408713-A1 | PHENYLSULPHONE DERIVATIVES. | ICI PLC (GB) | 1991-01-23 | — | — | EP | disclosed |
| WO-1990008761-A1 | PHENYLSULPHONE DERIVATIVES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1990-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203966-A1 | Nitromethylthiobenzene derivatives as aldose reductase inhihibitors | AKR1B1, ALDOA, AKR1C1 | ALDH1A1 48/4885PKM 621/4885KMT2A 4070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.